市場調查報告書
商品編碼
964923

登陸前基因測試的市場增長,趨勢和預測(2020-2025)

Preimplantation Genetic Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,植入前基因檢測的市場規模預計將以10.5%的複合年增長率增長。市場增長的主要因素是由於分娩過程中的併發症導致大量新生兒死亡,以及父母對診斷進展的意識增強。近年來,先天性遺傳疾病(如愛德華茲綜合徵)和常見的兒科呼吸系統疾病(如肺炎和哮喘)的患病率有所增加。根據聯合國兒童基金會(UNICEF)2018年11月發佈的估計,全世界每年約有300萬人死於兒童肺炎。這些疾病幾乎僅在遺傳性疾病的夫婦中發生,並且大多數在工業化國家中觀察到。因此,人們對早期診斷的需求不斷增長,以及政府加強管理醫療負擔的舉措,有望推動植入前基因檢測市場的發展。

在本報告中,我們將調查植入前基因測試市場,以及市場概況,以及按測試類型,產品/服務,應用,最終用戶,地區和進入市場的公司概況劃分的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場驅動力
    • 遺傳疾病的負擔增加,例如帕托綜合症,愛德華茲綜合症和唐氏病
    • 加強政府努力,以提高認識,開發先進的診斷設備並加強研發活動
  • 市場限制
    • 人口少和道德問題
    • 非常昂貴的檢查程序
    • 不利的監管框架和發展挑戰
  • 波特的五力分析

第5章市場細分

  • 按檢查類型
    • 植入前遺傳學診斷(PGD)
    • 植入前基因篩選(PGS)
  • 按產品/服務
    • 儀器
    • 試劑/消耗品
    • 軟件服務
  • 按應用
    • HLA輸入
    • IVF預後
    • 異構篩選
    • 其他
  • 最終用戶
    • 醫院和診斷實驗室
    • 婦產中心/生育診所
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東/非洲
    • 南美洲

第6章競爭情況

  • 公司簡介
    • The Cooper Companies Inc.
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Inc.
    • PerkinElmer Inc.
    • Invitae Corp.
    • Natera Inc.
    • Igenomix Sl
    • Bioarray SL
    • Genea Ltd

第7章 市場機會與將來動向

目錄
Product Code: 68439

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period. The major factor attributing to the growth of the market is a rising awareness among parents regarding advancements in diagnostics with a huge volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome, and common pediatric respiratory disorders such as pneumonia, and asthma are observed in recent years. As per the estimates published by the United Nations Children's Fund (UNICEF) in November 2018, about 3 million deaths occurred due to pediatric pneumonia worldwide each year. These abnormalities occur almost exclusively in couples with hereditary disorders, which was observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and a rise in government initiatives to control the healthcare burden is likely to drive the pre-implantation genetic testing market.

Key Market Trends

HLA Typing by Application Segment is Expected to Hold the Major Market Share in the Preimplantation Genetic Testing Market

The HLA typing by application segment is expected to account for the largest held the largest of the pre-implantation genetic testing market. Dominance can be owing to a rising volume of patients with damaged bone marrow or defective immune system. This results in an increased volume of hematopoietic stem cell transplantations (HSCT), necessitating the tests. Also, their increased application in evaluating interconnected matched donors and unrelated donors for safer HSCT is expected to drive the growth of the segment. On the other hand, inherited genetic disease testing is anticipated to witness the highest CAGR during the forecast period. The lucrative growth can be due to their ability to detect diseases in offspring and increased awareness among the public about the inheritance of these diseases by future generations. Furthermore, steep rising incidences of inherited genetic diseases, such as Marfan syndrome, cystic fibrosis, fragile X syndrome hemoglobin disorders, and others, are driving the growth of the segment.

North America Dominates the Market and it is Expected to do the Same in the Forecast Period

North America is expected to dominate the pre-implantation genetic testing market. The dominance is owing to a growing volume of chromosome abnormality cases leading to various genetic disorders. Aneuploidy is the most common causing Down syndrome among newborn babies in the united states, which holds the major revenue share in the North American market. According to the World Health Organization report published in 2018, down syndrome continues to be the most common chromosomal disorder affecting 6,000 babies born in the United States each year. This, in turn, resulted in high demand for earlier diagnosis to identify the genetic defects in embryos drive the market in the region. Launch of new products by key players and a rise in improvements in healthcare infrastructure in the United States generates more revenue. Rise in government initiatives to create awareness in public and growing preference among couples for these tests during IVF and other artificial insemination procedures further stimulate the growth of the preimplantation genetic testing market in the region.

Competitive Landscape

The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and the launch of new products. In October 2019, PerkinElmer launched PG-Seq Rapid Non-Invasive Pre-implantation Genetic Testing Kit for Aneuploidy (PGT-A). It is a non-invasive alternative to conventional IVF embryo biopsies, which is expected to impact the market positively. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome
    • 4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices
  • 4.3 Market Restraints
    • 4.3.1 Small Size of Study Population and Ethical Concerns
    • 4.3.2 Highly Expensive Testing Procedures
    • 4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Test Type
    • 5.1.1 Preimplantation Genetic Diagnosis (PGD)
    • 5.1.2 Preimplantation Genetic Screening (PGS)
  • 5.2 Product and Service
    • 5.2.1 Instruments
    • 5.2.2 Reagents and Consumables
    • 5.2.3 Software and Services
  • 5.3 Application
    • 5.3.1 HLA Typing
    • 5.3.2 IVF Prognosis
    • 5.3.3 Aneuploidy Screening
    • 5.3.4 Other Applications
  • 5.4 End User
    • 5.4.1 Hospitals and Diagnostic Labs
    • 5.4.2 Maternity Centers and Fertility Clinics
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 The Cooper Companies Inc.
    • 6.1.2 Illumina Inc.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Quest Diagnostics Inc.
    • 6.1.5 PerkinElmer Inc.
    • 6.1.6 Invitae Corp.
    • 6.1.7 Natera Inc.
    • 6.1.8 Igenomix Sl
    • 6.1.9 Bioarray SL
    • 6.1.10 Genea Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS